{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["27(7)"],"submitter":["Zeng Y"],"pubmed_abstract":["The resected pⅢA-N2 non-small-cell lung cancer (NSCLC) patients who could benefit from postoperative radiotherapy (PORT) are not well-defined. The study explored the role of PORT on EGFR mutant and wild-type NSCLC patients. We retrospectively searched for resected pIIIA-N2 lung adenocarcinoma patients who underwent EGFR mutation testing. 80 patients with EGFR wild-type and 85 patients with EGFR mutation were included. 62 patients received PORT. In overall population, the median disease-free survival (DFS) was improved in PORT arm compared to non-PORT arm (22.9 vs. 16.1 months; <i>p</i> = 0.036), along with higher 2-year locoregional recurrence-free survival (LRFS) rate (88.3% vs. 69.3%; <i>p</i> = 0.004). In EGFR wild-type patients, PORT was associated with a longer median DFS (23.3 vs. 17"],"journal":["iScience"],"pagination":["110219"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11253153"],"repository":["biostudies-literature"],"pubmed_title":["The efficacy of postoperative radiotherapy in resected pⅢA-N2 EGFR mutant and wild-type lung adenocarcinoma."],"pmcid":["PMC11253153"],"pubmed_authors":["Zhang YZ","He FJ","Peng YR","Liu JQ","Qiu ZH","Pu XX","Li YL","Zhu H","Huang K","Zeng Y","Shi SH","Wu F","Zou JA","Deng C","Liu XL","Hu CH","Huang Y","Liu YF","Ma F"],"additional_accession":[]},"is_claimable":false,"name":"The efficacy of postoperative radiotherapy in resected pⅢA-N2 EGFR mutant and wild-type lung adenocarcinoma.","description":"The resected pⅢA-N2 non-small-cell lung cancer (NSCLC) patients who could benefit from postoperative radiotherapy (PORT) are not well-defined. The study explored the role of PORT on EGFR mutant and wild-type NSCLC patients. We retrospectively searched for resected pIIIA-N2 lung adenocarcinoma patients who underwent EGFR mutation testing. 80 patients with EGFR wild-type and 85 patients with EGFR mutation were included. 62 patients received PORT. In overall population, the median disease-free survival (DFS) was improved in PORT arm compared to non-PORT arm (22.9 vs. 16.1 months; <i>p</i> = 0.036), along with higher 2-year locoregional recurrence-free survival (LRFS) rate (88.3% vs. 69.3%; <i>p</i> = 0.004). In EGFR wild-type patients, PORT was associated with a longer median DFS (23.3 vs. 17","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2025-04-04T15:02:30.648Z","creation":"2025-04-04T15:02:30.648Z"},"accession":"S-EPMC11253153","cross_references":{"pubmed":["39021795"],"doi":["10.1016/j.isci.2024.110219"]}}